Distribution of GAP-43 in relation to CGRP and synaptic vesicle markers in rat skeletal muscles during development.
GAP 43 in nerve terminal structures of rat skeletal muscles, was investigated during postnatal development using immunofluorescence and confocal laser scanning microscopy. Comparison with synaptophysin, synapsin, SV2, CGRP, SP and NF was done in double immunoincubation studies. GAP 43-like immunoreactivity (LI) was demonstrated in preterminal axons and motor endplates in all age groups (from E18 to adult), although the intensity of immunofluorescence was considerably higher in the younger rats. The outgrowing nerve sprouts in E18 muscles were strongly GAP 43-positive. The intensity decreased with increasing age, but even in adult animals GAP 43-LI was present in some p38- or SV2-positive endplates. GAP 43-LI was also present in muscle spindles and preterminal nerve branches, and likewise decreased with age. Perivascular nerve terminals (around arteries mainly) were, however, strong in GAP 43-LI during both development and adulthood. GAP 43-LI was strong, and present in both small and large granules. SP-LI was observed in a few thin, presumably sensory, axons around vessels, which also contained a few GAP 43-positive large granules. Most of the strongly GAP 43-positive terminals around vessels were probably autonomic postganglionic terminals. The results suggest that GAP 43, in addition to development and regeneration, may play a significant role also in normal adult rats, especially in perivascular nerve terminals, possibly connected with a high potential for plasticity in this kind of nerve terminals.
Li
J Y
JY
Department of Anatomy and Cell Biology, University of Göteborg, Sweden.
Dahlström
A B
AB
D000375:Aging / Q000378:metabolism; D000818:Animals; D015415:Biomarkers; D015740:Calcitonin Gene-Related Peptide / Q000276:immunology / Q000378:metabolism*; D005260:Female; D019922:GAP-43 Protein; D007150:Immunohistochemistry; D008297:Male; D008562:Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism*; D009045:Motor Endplate / Q000378:metabolism; D024510:Muscle Development; D009132:Muscles / Q000294:innervation / Q000378:metabolism*; D009411:Nerve Endings / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000276:immunology / Q000378:metabolism*; D016900:Neurofilament Proteins / Q000276:immunology / Q000378:metabolism*; D009473:Neuronal Plasticity / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013373:Substance P / Q000276:immunology / Q000378:metabolism; D016704:Synapsins / Q000276:immunology / Q000378:metabolism; D013572:Synaptic Vesicles / Q000378:metabolism*; D016708:Synaptophysin / Q000276:immunology / Q000378:metabolism
D015415:Biomarkers; D019922:GAP-43 Protein; D008562:Membrane Glycoproteins; D009419:Nerve Tissue Proteins; D016900:Neurofilament Proteins; D016704:Synapsins; D016708:Synaptophysin; D013373:Substance P; D015740:Calcitonin Gene-Related Peptide